Literature DB >> 17914348

CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation.

C R C van Roeyen1, F Eitner, T Scholl, P Boor, U Kunter, N Planque, H-J Gröne, A M Bleau, B Perbal, T Ostendorf, J Floege.   

Abstract

CCN proteins affect cell proliferation, migration, attachment, and differentiation. We identified CCN3 as a suppressed gene following platelet-derived growth factor (PDGF)-BB or -DD stimulation in a cDNA-array analysis of mesangial cells. In vitro growth-arrested mesangial cells overexpressed and secreted CCN3, whereas the addition of the recombinant protein inhibited cell growth. Induction of mesangial cell proliferation by PDGF-BB or the specific PDGF beta-receptor ligand PDGF-DD led to downregulation of CCN3 mRNA, confirming the array study. Specific PDGF alpha-receptor ligands had no effect. CCN3 protein was found in arterial smooth muscle cells, the medullary interstitium, and occasional podocytes in the healthy rat kidney. Glomerular CCN3 was low prior to mesangial proliferation but increased as glomerular cell proliferation subsided during mesangioproliferative glomerulonephritis (GN). Inhibition of PDGF-B in mesangioproliferative disease led to overexpression of glomerular CCN3 mRNA. CCN3 localized mostly to podocytes in human glomeruli, but this expression varied widely in different human glomerulonephritides. Glomerular cell proliferation negatively correlated with CCN3 expression in necrotizing GN. Our study identifies CCN3 as an endogenous inhibitor of mesangial cell growth and a modulator of PDGF-induced mitogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914348     DOI: 10.1038/sj.ki.5002584

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

2.  The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1-6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1-3 respectively.

Authors:  Bernard Perbal; Susan Tweedie; Elspeth Bruford
Journal:  J Cell Commun Signal       Date:  2018-11-05       Impact factor: 5.782

3.  CCN3: a novel anti-fibrotic treatment in end-stage renal disease?

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2012-03-16       Impact factor: 5.782

4.  CCN proteins: A centralized communication network.

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2013-02-19       Impact factor: 5.782

Review 5.  The concept of the CCN protein family revisited: a centralized coordination network.

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2018-02-22       Impact factor: 5.782

Review 6.  Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers.

Authors:  Andrew Leask
Journal:  Am J Physiol Cell Physiol       Date:  2020-03-04       Impact factor: 4.249

7.  CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC.

Authors:  Erawan Borkham-Kamphorst; Claudia R van Roeyen; Eddy Van de Leur; Jürgen Floege; Ralf Weiskirchen
Journal:  J Cell Commun Signal       Date:  2011-07-05       Impact factor: 5.782

8.  Cold Shock Proteins Mediate GN with Mesangioproliferation.

Authors:  Cheng Zhu; Eva Sauter; Anja Schreiter; Claudia R C van Roeyen; Tammo Ostendorf; Jürgen Floege; Florian Gembardt; Christian P Hugo; Berend Isermann; Jonathan A Lindquist; Peter R Mertens
Journal:  J Am Soc Nephrol       Date:  2016-05-05       Impact factor: 10.121

9.  CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro.

Authors:  Hai-Fei Liu; Hong Liu; Lin-Li Lv; Kun-Ling Ma; Yi Wen; Long Chen; Bi-Cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

10.  CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.

Authors:  Bruce L Riser; Feridoon Najmabadi; Bernard Perbal; Darryl R Peterson; Jo Ann Rambow; Melisa L Riser; Ernest Sukowski; Herman Yeger; Sarah C Riser
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.